279
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience

, , , , , , , , , , , , , & show all
Pages 1057-1062 | Received 20 May 2020, Accepted 06 Jul 2020, Published online: 21 Jul 2020
 

Abstract

Background

The prognosis for advanced Hepatocellular carcinoma (HCC)is still very poor. Despite initial usefulness of immune checkpoint inhibitor (PD-1), phase 3 trials failed to show significant benefit of PD-1 inhibition with nivolumab or pembrolizumab in the first and second line therapy of HCC. Clinical evidence of PD-1 inhibition in patients with advanced and heavily pretreated HCC outside clinical trials is extremely limited. In this study, we analyzed the clinical experience with PD-1 inhibition in patients with heavily pretreated HCC.

Methods

Between May 2016 and January 2019 14 patients with advanced and heavily pretreated HCC were treated with nivolumab or pembrolizumab at the University Hospital Bonn, Germany. Base line characteristics prior to immunotherapy, immunohistochemistry of different immunological markers, beneficial outcome and safety were recorded and retrospectively analyzed.

Results

Immunotherapy with PD-1 inhibition was well tolerated and resulted in significant clinical benefit as last line therapy. Median overall survival (OS) was 6.6 months (95%CI:3.9–11.8), progression-free survival (PFS) was 5.3 months (95%CI:2.4–11.7) and overall response rate (ORR) was 30.8%. One patient reached a complete remission.

Conclusions

Despite numerous pretreatments, PD-1 inhibition was well tolerated and showed clinical benefit in patients with heavily pretreated HCC.

Acknowledgements

The authors thank Ms. Kathrin Brinkmann and Ms. Sonja Hebold for their extremely valuable support and assistance in this work.

Disclosure statement

All authors approved the final version of the manuscript. None of the authors have any potential conflicts (financial, professional or personal) that are relevant to the manuscript. Maria A. Gonzalez-Carmona has contributed to advisory board for BMS, Eisai, Amgen, IPSEN and Roche.

Additional information

Funding

This work was supported by the following grants awarded to M.A. Gonzalez-Carmona: GO 1874/1-2 grant from the ‘Deutsche Forschungsgemeinschaft’ (DFG), BONFOR from the University of Bonn, grant number 109255 from the ‘Deutsche Krebshilfe’ (German Cancer Aid) and grant from the Reuthersche endowment fund of the University of Bonn.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 336.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.